Fig. 3From: Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscapeDough-nut plot showing the percentage of patients with clinically actionable (Tier I and Tier II) and non-actionable (Tier III) genetic alterations detected by NGS in the study group (N = 100, Lung cancer patients)Back to article page